GANX - Gain Therapeutics Inc. Appoints Gene Mack as Interim CEO | Benzinga
Mr. Mack is the Company's Current CFO
Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman
BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder's departure, the Company appointed Gene Mack, the Company's current Chief Financial Officer, as interim Chief Executive Officer, effective June 25, 2024. Mr. Mack will retain his role as Chief Financial Officer. Khalid Islam, Ph.D., founder and Chairman of the Company's Board of Directors, will bolster management as Executive Chairman until a permanent CEO is appointed.
"On behalf of Gain, I would like to thank Matthias for his significant contribution to the development of our company, as we advanced our lead candidate, GT-02287, into clinical development. Matthias played an instrumental role building the preclinical dossier for GT-02287 including the most recent positive data presented this week at FENS Forum 2024, in which administration of GT-02287 was associated with significant improvement in cognitive performance and other related activities of daily living in a preclinical model of GBA1 Parkinson's disease. We look forward to the continued advancement of GT-02287 and the potential positive impact we believe it may have on Parkinson's Disease patients," stated Dr. Islam.
About GT-02287
Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease. The orally administered, brain-penetrant small molecule is an ...